Richard Markus Biography and Net Worth

Insider of Arcus Biosciences

Dr. Markus brings over 20 years of experience in biopharmaceuticals and clinical development to his role as chief medical officer at Arcus. Dr. Markus established a unique track record of late-stage development experience during a 13-year tenure at Amgen in increasing roles of responsibility, including as vice president of global development. Dr. Markus oversaw the development and approval of multiple products and was also the first R&D head for the biosimilars division, leading the development of a 10-product pipeline across multiple therapeutic areas, including oncology and rheumatology. He also oversaw the development that led to the approval of CAYSTON® for cystic fibrosis at Corus Pharma prior to its acquisition by Gilead. Most recently, Dr. Markus founded Dantari, a clinical-stage oncology-focused antibody-drug conjugate company, where he served as president, CEO and member of the Board. Dr. Markus received his M.D. and a Ph.D. in epidemiology from the University of Southern California.

What is Richard Markus' net worth?: The estimated net worth of Richard Markus is at least $1.48 million as of December 16th, 2025. Markus owns 70,141 shares of Arcus Biosciences stock worth more than $1,482,079 as of February 10th. This net worth evaluation does not reflect any other assets that Markus may own. Learn More about Richard Markus' net worth.
How do I contact Richard Markus?: The corporate mailing address for Markus and other Arcus Biosciences executives is 3928 Point Eden Way, Hayward CA, 94545. Arcus Biosciences can also be reached via phone at (510) 694-6200 and via email at [email protected]. Learn More on Richard Markus' contact information.
Has Richard Markus been buying or selling shares of Arcus Biosciences?: Richard Markus has not been actively trading shares of Arcus Biosciences over the course of the past ninety days. Most recently, Richard Markus sold 4,494 shares of the business's stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $22.16, for a transaction totalling $99,587.04. Following the completion of the sale, the insider now directly owns 65,647 shares of the company's stock, valued at $1,454,737.52. Learn More on Richard Markus' trading history.
Who are Arcus Biosciences' active insiders?: Arcus Biosciences' insider roster includes Alexander Azoy (CAO), Robert Goeltz II (CFO), Juan Jaen (President), Jennifer Jarrett (COO), Yasunori Kaneko (Director), Richard Markus (Insider), Terry Rosen (CEO), and Carolyn Tang (General Counsel). Learn More on Arcus Biosciences' active insiders.
Are insiders buying or selling shares of Arcus Biosciences?: During the last twelve months, Arcus Biosciences insiders bought shares 2 times. They purchased a total of 39,800 shares worth more than $402,764.00. During the last twelve months, insiders at the sold shares 29 times. They sold a total of 476,762 shares worth more than $10,092,282.74. The most recent insider tranaction occured on January, 5th when President Juan C Jaen sold 31,823 shares worth more than $681,330.43. Insiders at Arcus Biosciences own 9.6% of the company. Learn More about insider trades at Arcus Biosciences.
Information on this page was last updated on 1/5/2026.

Richard Markus Insider Trading History at Arcus Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/17/2025	Sell	4,494	$22.16	$99,587.04	65,647
12/16/2025	Sell	5,052	$21.88	$110,537.76	70,141

Richard Markus Buying and Selling Activity at Arcus Biosciences

Arcus Biosciences Company Overview

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Today's Range

Now: $21.13

$20.44

$21.23

50 Day Range

MA: $22.75

$19.97

$25.82

2 Week Range

Now: $21.13

$6.50

$26.40

Volume

567,801 shs

Average Volume

1,072,414 shs

Market Capitalization

$2.28 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84